Does Dyspnoea during dipyridamole cardiac stress testing indicate bronchospasm and is the pretest clinical history predictive of this side-effect?

Leitha, Thomas; Gwechenberger, Marianne; Falger-Banyai, Susanne

doi:10.1007/bf01791149

Cited by 7 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dipyridamole is thought to act by blocking the reuptake of adenosine, and its safety in patients without airways disease undergoing myocardial perfusion imaging has been established [1,2]. Controversy exists regarding the safety and tolerability of dipyridamole in patients with severe COPD however [3,4], and it is contraindicated in patients with asthma [5].…”

Section: Introductionmentioning

confidence: 99%

The safety and tolerability of adenosine in patients with obstructive airways disease

Gaal¹,

Couthino²,

Chan³

et al. 2008

International Journal of Cardiology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

The safety and tolerability of adenosine in patients with obstructive airways disease

Gaal¹,

Couthino²,

Chan³

et al. 2008

International Journal of Cardiology

View full text Add to dashboard Cite

Practicability and safety of dipyridamole cardiac imaging in patients with severe chronic obstructive pulmonary disease

Thurnheer

Laube

Kaufmann

et al. 1999

European Journal of Nuclear Medicine and Molecular Imaging

View full text Add to dashboard Cite

We tested the practicability of dipyridamole myocardial nitrogen-13 ammonia positron emission tomography (dipyridamole (13)NH(3 )PET) for the perioperative risk assessment of coronary artery disease (CAD) in a cohort of patients with severe chronic obstructive pulmonary disease (COPD) undergoing lung volume reduction surgery (LVRS). Twenty consecutive LVRS candidates, 13 men and 7 women (mean age 57+/-2 years), without symptoms of CAD were prospectively studied by dipyridamole (13)NH(3 )PET. Side-effects and overall tolerance were assessed by a questionnaire and visual analogue scale. Repeated pulmonary function tests were performed before and 4, 12, 16 and 30 minutes after dipyridamole injection. All dipyridamole (13)NH(3 )PET studies were negative for CAD. Seventeen patients underwent LVRS without cardiac complications; three patients did not undergo LVRS for other reasons. Nine patients suffered intolerable dyspnoea requiring i.v. aminophylline. Mean FEV(1) decreased significantly after dipyridamole infusion: in nine patients the reduction in FEV(1)exceeded 15% from baseline. We found that dipyridamole is not well tolerated and causes significant bronchoconstriction in patients with severe COPD. Although all dipyridamole-induced side effects can be promptly reversed by aminophylline, dipyridamole cannot be recommended as a pharmacological stress in this setting.

show abstract

The safety of dipyridamole in patients undergoing myocardial perfusion scintigraphy prior to lung volume reduction surgery

et al. 2001

View full text Add to dashboard Cite

Patients with end-stage chronic obstructive pulmonary disease (COPD) undergoing lung volume reduction surgery (LVRS) are at high risk of peri-operative cardiac complications, and myocardial perfusion scintigraphy (MPS) is commonly used for risk stratification. This study prospectively assessed the safety of dipyridamole in these patients and compared the incidence of side-effects (particularly dyspnoea) with that in patients undergoing dipyridamole MPS prior to elective non-cardiothoracic surgery. Fifty patients were enrolled: 25 in the LVRS cohort (13 males, 12 females), with a mean age of 65 years and a mean FEV1 of 0.791, and 25 (with no history of asthma or COPD) in the control cohort (14 males, 11 females), with a mean age of 66 years. Fourteen patients (56%) in each group developed side-effects. Dyspnoea was reported by five patients (20%) in the LVRS and two patients (8%) in the control cohort (P=NS). One patient in each cohort developed severe hypotension and bradycardia. Eight (32%) other patients developed minor side-effects in the LVRS cohort compared with 11 (44%) in the control group. All side-effects responded promptly to intravenous aminophylline. In summary, there was a statistically non-significant increase in the incidence of dyspnoea in patients with end-stage COPD and all side-effects responded to aminophylline. Thus, dipyridamole can be used safely in these patients.

show abstract

Does Dyspnoea during dipyridamole cardiac stress testing indicate bronchospasm and is the pretest clinical history predictive of this side-effect?

Cited by 7 publications

References 9 publications

The safety and tolerability of adenosine in patients with obstructive airways disease

The safety and tolerability of adenosine in patients with obstructive airways disease

Practicability and safety of dipyridamole cardiac imaging in patients with severe chronic obstructive pulmonary disease

The safety of dipyridamole in patients undergoing myocardial perfusion scintigraphy prior to lung volume reduction surgery

Contact Info

Product

Resources

About